Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EP300_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EP300_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EP300_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EP300_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EP300_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EP300_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003096818 | Esophagus | ESCC | endoplasmic reticulum unfolded protein response | 59/8552 | 74/18723 | 1.90e-09 | 4.36e-08 | 59 |
GO:1901796111 | Esophagus | ESCC | regulation of signal transduction by p53 class mediator | 70/8552 | 93/18723 | 5.69e-09 | 1.18e-07 | 70 |
GO:0042771110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 38/8552 | 43/18723 | 5.75e-09 | 1.18e-07 | 38 |
GO:0072332111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway by p53 class mediator | 59/8552 | 76/18723 | 1.22e-08 | 2.42e-07 | 59 |
GO:0051101111 | Esophagus | ESCC | regulation of DNA binding | 84/8552 | 118/18723 | 1.64e-08 | 3.21e-07 | 84 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
GO:00059969 | Esophagus | ESCC | monosaccharide metabolic process | 159/8552 | 257/18723 | 1.11e-07 | 1.81e-06 | 159 |
GO:001908312 | Esophagus | ESCC | viral transcription | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
GO:0009408110 | Esophagus | ESCC | response to heat | 77/8552 | 110/18723 | 2.01e-07 | 3.11e-06 | 77 |
GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
GO:00193189 | Esophagus | ESCC | hexose metabolic process | 147/8552 | 237/18723 | 2.63e-07 | 3.94e-06 | 147 |
GO:00715599 | Esophagus | ESCC | response to transforming growth factor beta | 157/8552 | 256/18723 | 2.95e-07 | 4.23e-06 | 157 |
GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
EP300 | BAS | Skin | SCCIS | AC104365.1,STX18-AS1,VASN, etc. | 1.89e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Skin/Str/TF_SCCIS/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | ADJ | AL096865.1,MACF1,DDX17, etc. | 5.60e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | PTC | AL096865.1,MACF1,DDX17, etc. | 4.33e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_PTC/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ADJ | SECISBP2L,NKRF,SYNE2, etc. | 3.30e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ATC | SECISBP2L,NKRF,SYNE2, etc. | 1.17e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ATC/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP300 | SNV | Missense_Mutation | | c.5528A>C | p.Gln1843Pro | p.Q1843P | Q09472 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EP300 | SNV | Missense_Mutation | | c.6023N>T | p.Ser2008Phe | p.S2008F | Q09472 | protein_coding | tolerated(0.06) | benign(0.203) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
EP300 | SNV | Missense_Mutation | rs769721803 | c.1349N>T | p.Ala450Val | p.A450V | Q09472 | protein_coding | tolerated(0.07) | possibly_damaging(0.771) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EP300 | SNV | Missense_Mutation | rs775556373 | c.5854N>G | p.Ile1952Val | p.I1952V | Q09472 | protein_coding | tolerated(0.33) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.4352N>C | p.His1451Pro | p.H1451P | Q09472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EP300 | SNV | Missense_Mutation | | c.4608A>T | p.Glu1536Asp | p.E1536D | Q09472 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EP300 | SNV | Missense_Mutation | | c.2498N>T | p.Ser833Leu | p.S833L | Q09472 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.980C>T | p.Ala327Val | p.A327V | Q09472 | protein_coding | tolerated(0.08) | possibly_damaging(0.833) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
EP300 | SNV | Missense_Mutation | novel | c.2744G>T | p.Arg915Leu | p.R915L | Q09472 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
EP300 | SNV | Missense_Mutation | novel | c.1440N>A | p.Met480Ile | p.M480I | Q09472 | protein_coding | tolerated(0.54) | benign(0.076) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103579 | CURCUMIN | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103614 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-UNDECYLIDENEMALONATE | CHEMBL1797707 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 187051830 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 249565916 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-PENTADECYLIDENEMALONATE | CHEMBL404916 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103615 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103578 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 |